Method of treating leukopenia with adenosine

Details Method of treating leukopenia with adenosine Method of treating leukopenia with adenosine

2005-06-28

2005-06-28

Wilson, James O. (Department: 1609)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

Reexamination Certificate

active

06911435

ABSTRACT:
Adenosine and active agent which interact with the adenosine system are used to treat conditions of weakened, immune system, as an anti-cancer therapy and for improving the therapeutic index of a variety of therapeutic drugs.

REFERENCES:
patent: 4364922 (1982-12-01), Berne et al.
patent: 4673563 (1987-06-01), Berne et al.
patent: 5104859 (1992-04-01), Sollevi
patent: 5145771 (1992-09-01), Lemasters et al.
patent: 5231086 (1993-07-01), Sollevi
patent: 5449665 (1995-09-01), Sollevi
patent: 5534504 (1996-07-01), Sollevi
patent: 5648341 (1997-07-01), Sollevi
patent: 5677290 (1997-10-01), Fukunaga
patent: 5679650 (1997-10-01), Fukunaga et al.
patent: 5686114 (1997-11-01), Welsh
patent: 5731296 (1998-03-01), Sollevi
patent: 5882927 (1999-03-01), Bennett et al.
patent: 5958907 (1999-09-01), Welsh
patent: 2001/0031742 (2001-10-01), Fishman et al.
patent: 2002/0037871 (2002-03-01), Fishman et al.
patent: 0066918 (1982-12-01), None
patent: 797237 (1958-07-01), None
patent: WO 94/17809 (1994-08-01), None
patent: WO 00/10760 (2000-03-01), None
patent: WO 00/40251 (2000-07-01), None
patent: WO 01/19360 (2001-03-01), None
patent: WO 02/09701 (2002-07-01), None
Drury et al., “The Physiological Activity of Adenine Compounds with Especial Reference to their Action Upon the Mammalian Heart,”Journal of Physiology(Cambrige),68, 213-237 (1929).
Sollevi (VII), “Cardiovascular Effects of Adenosine in Man; Possible Clinical Implications,”Progress in Neurobiology, 27, 319-349 (1986).
Homeister et al., “Combined Adenosine and Lidocaine Administration Limits Myocardial Reperfusion Injury,”Circulation, 82(2), 595-608 (Aug., 1990).
Newberg et al., “Cerebral and Systemic Effects of Hypotension Induced by Adenosine or ATP in Dogs,”Anesthesiology, 62(4), 429-436 (Apr., 1985).
Berkow et al. (eds.),The Merck Manual of Diagnosis and Therapy, 16th Edition, Merck & Co., Rahway, NJ, May, 1992, only pp. 1225-1243 supplied.
Calabresi et al., “Antineoplastic Agents,” Ch. 52 inGoodman and Gilman's The Pharmacological Basis of Therapeutics, Eighth Edition, Gilman et al. (eds.), Pergamon Press, 1990, New York, NY, only pp. 1209 & 1215-1219 supplied.
Rall, “Drugs Used in the Treatment of Asthma,” Ch. 25 inGoodman and Gilman's The Pharmacological Basis of Therapeutics, Eighth Edition, Gilman et al. (eds.), Pergamon Press, 1990, New York, NY, only pp. 618 & 624-625 supplied.
Boyd et al., “The Neutralization of Aminopterin-Induced Leukopenia by Adenosine-5-phosphoric Acid,”Journal of Laboratory and Clinical Medicine, 41, 931-935 (1953);Chemical Abstracts, 47(19), Abstract No. 10116c-e (Oct. 10, 1953); CAPlus cite is “1953: 59519.”
Matsumoto et al., “Nucleoside-Nucleotide Mixture Increases Peripheral Neutrophils in Cyclophosphoramide-Induced Neutropenic Mice,”Nutrition, 11(3), 296-299 (May/Jun., 1995);Chemical Abstracts, 123(19), pages 1043-1044, Abtract No. 255501q (Nov. 6, 1995).
Lejnieks et al., “Granulocyte Colony-Stimulation Factor Expression from Transduced Vascular Smooth Muscle Cells Provides Sustained Neutrophil Increases in Rats,”Human Gene Therapy, 7, 1431-1436 (Aug. 1, 1996).
Thiel et al., “Effects of Adenosine on the Functions of Circulating Polymorphonuclear Leukocytes during Hyperdynamic Endotoxemia,”Infection and Immunity, 65(6), 2136-2144 (Jun., 1997).
Roy et al., “A Single Amino Acid Difference within the Folate Transporter Encoded by the Murine RFC-1 Gene Selectively Alters its Interaction with Folate Analogues,”Journal of Biological Chemistry , 273(5), 2526-2531 (Jan. 30, 1998).
Matherly et al., “Enhanced Polyglutamylation of Aminopterin Relative to Methotrexate in the Ehrlich Ascites Tumor Cell in Vitro,”Cancer Research, 45, 1073-1078 (Mar., 1985).
Marshall et al., “General Anesthetics,” Ch. 14 inGoodman and Gilman's The Pharmacological Basis of Therapeutics, Eighth Edition, Gilman et al. (eds.), Pergamon Press, 1990, New York, NY, only pp. 298-300 supplied (see p. 300, col. 1, for vitamin B-12-related side effects of Nitrous Oxide).
Fukunaga et al. (II), “Hypotensive Effects of Adenosine and Adenosine Triphosphate Compared with Sodium Nitroprusside,”Anesthesia and Analgesia, 61(3), 273-278 (Mar., 1982).
Hirano et al., “Functional Coupling of Adenosine A2aReceptor Inhibiton of the Mitogen-Activated Protein Kinase Cascade in Chinese Hamster Ovary Cells,”Biochemical Journal, 316(Pt. 1), 81-86 (May 15, 1996).
M.G. Collis, The Vasodilator Role of Adenosine, Pharmacology & Therapeutics, vol. 41, No. 1/2, The Journal of The International Encyclopedia of Pharmacology and Therapeutics, 1989, pp. 143-162, Month of publication could not be determined from copy supplied.
I. Barasoain et al., Isoprinosine Restores in Vitro T Lymphocyte Functions of Cyclophosphamide Immunosuppressed Mice, Int. J. Immunopharmac., vol. 9, No. 4, 1987, XP002083810, pp-489-496, Month of publication data is unavailable for this reference.
J.E.F. Reynolds, Ed. -The Martindale Extra Pharcamocopoeia, 31stEdition, 1996-Royal Pharmaceutical Society, London XP002083816, pp. 813-814,Month of publication data is unavailable for this reference.
J. Epstein et al., Protection of normal Hematopoietic Stem Cells from the Toxicity of Purine Base Analogs: In Vivo Application, Cancer Treatment Reports, vol. 68, No. 9, 1984, XP002083811, pp. 1153-1156, Month of publication data is unavailable for this reference.
R.C. Jackson et al., Biochemical Approaches to Enhancement of Antitumor Drug Selectivity: Selective Protection of Cells from 6-Thioguanine and 6-Mercaptopurine by Adenosine—Cancer Treatment Reports, vol. 64, No. 12, 1980, XP002083812, pp. 1347-1353 Dec., 1980).
M. Debatisse et al., The Control of Cell Proliferation by Preformed Purines: A Genetic Study. II. Pleiotropic Manifestations and Mechanism of a Control Exerted by Adenylic Purines on PRPP Synthesis, Somatic Cell Genetics, vol. 3, No. 5, 1997, XP002083813, pp. 513-527, Month of publication data is unavailable for this reference.
P. Gentile et al., Approaches to Ablating the Myelotoxicity of Chemotherapy, CRC Critical Reviews in Oncology/Hematology, vol. 7, 1987, XP002083814, pp. 73-75, Month of publication data is unavailable for this reference.
Y.-X. Feng et al., Suppressive effects of adenosine on nonspecific and humoral immunities in mice, Dialog (R) File 73: Embase, Accession No. 9340892: ACTA Pharmacol. Sin., vol. 15, No. 5, 1994, XP002083815, pp. 473-476, Month of publication data is unavailable for this reference.
M. Iigo et al., Relationship between Antitumor Effect and Metabolites of 5-Fluorouracil in Combination Treatment with 5-Fluorouracil and Guanosine in Ascites Sarcoma 180 Tumor System, Cancer Res., vol. 43, No. 12, Pt. 1, 1983, XP002102063, pp. 5687-5694 (Dec., 1983).
E. Rapaport, Experimental Cancer Therapy in Mice by Adenine Nucleotides, Eur. J. Cancer Clin. Oncol., vol. 24, No. 9, 1988, XP002102064, pp. 1491-1497, Month of publication data is unavailable for this reference.
H.B. Tey et al., Adenosine Modulates Cell Growth in Human Epidermoid Carcinoma (A431) Cells, Biochem. Biophys. Res. Commun., vol. 187, No. 3, 1992, XP002102065, pp. 1486-1492 (Sep. 30, 1992).
Q. Wang et al., Antineoplastic action of adenosine triphosphate, Dialog (R) File 159: Cancerlit (C): Accession No. 01001704: Chung Hua I Hsueh Tsa Chih, vol. 73, No. 7, 1993, XP002102066, pp. 434-436, Month of publication data is unavailable for this reference.
E. Rapaport et al., Anticancer activites of adenine nucleotides in mice are mediated through expansion of erythrocyte ATP pools, Proc. Natl. Acad. Sci., USA, vol. 86, 1989, XP002102067, pp. 1662-1666 (Mar., 1989).
G.B. Grindey et al., Antitumor Activity of N6-Phenyladenosine, an Inhibitor of Adenosine Utilization, in Combination with Related Purine Analogs, Cancer Res., vol. 33, 1973, XP002102068, pp. 2459-2463 (Oct., 1973).
M. Tezuka et al., Potentiation of the Antitumor Effects of 5-Fluorouracil by Some Nucle

Affiliated with

Also associated with

Rating

Method of treating leukopenia with adenosine does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of treating leukopenia with adenosine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating leukopenia with adenosine will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3463373